Skip to main content
OpenTrials
Completed

NCT Number: NCT02117037

Prognostic Value of Biomarkers Associated With Endothelial Progenitor Cells Mobilization in Acute Coronary Syndromes

This prospective study aimed to validate a new prognostic approach of endothelial progenitor cells associated biomarkers in patients with acute coronary syndromes . Recruitment is made prospectively by two centers of Inter -region South Mediterranean,

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Coronary Syndromes Acute Coronary Syndrome Cardiovascular Diseases Heart Diseases Myocardial Ischemia Vascular Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

assistance Publique Hopitaux de Marseille

Marseille, 13015, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • acute coronary syndrome (ST + < 12 hours and ST- high risk or intermediate risk ),which there is an indication of percutaneous coronary intervention.

Exclusion criteria

  • Cancer
  • Chronic inflammatory disease
  • Infectious disease
  • Erythrocyte <4 G/l
  • Thrombopénia less than 100 000/mm3 ;

Treatment and study plan

blood sample

Other

Primary outcomes

  1. evaluate the value of circulating endothelial progenitor cells quantification in the initial phase of ACS in predicting the occurrence of a major cardiovascular event (ECVM ) at 1 year.

    Time frame: one year

Secondary outcomes

  1. determine the technical characteristics (sensitivity and specificity) and predictive value of the number of PEC

    Time frame: one day , one month , one year

Other outcomes

  1. determine the technical characteristics (sensitivity and specificity) and performance (technical and predictive) of chemokines / receptors expression in the occurrence of ECVM

    Time frame: one day, one month ,one year

  2. Determine the above performance in the subgroup of patients defined as incompletely revascularized (at least a residual stenosis < 70%)

    Time frame: one year

Sponsors and collaborators

Lead sponsor

Assistance Publique Hopitaux De Marseille

Other

Registry information

Important dates

Study start
2014
Primary completion
2017
Study completion
2018
First posted
Apr 17, 2014
Registry last updated
May 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.